Translational analyses show stronger immune fitness and a more immunocompetent TME when CARVYKTI® is used earlier in the treatment journey Eighty percent of as-treated patients in CARTITUDE-4 with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback